EICHORPublic-registry site landscape for NCT07752875, “A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation”, a Ovarian Cancer study sponsored by LG Chem. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07752875 (registry record) |
| Study title | A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation |
| Official title | A Phase 1/2, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation |
| Sponsor | LG Chem |
| Condition(s) | Ovarian Cancer; Small Cell Lung Cancer; Non Small Cell Lung Cancer; Colorectal Cancer |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 0 |
| Intervention(s) | LG00313112 |
Patient-friendly overview of this study: eichor.com/study/NCT07752875.
Eichor generates a preliminary site-risk snapshot for NCT07752875 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
